On Nov 19, major Wall Street analysts update their ratings for $Syndax Pharmaceuticals (SNDX.US)$, with price targets ranging from $33 to $51.
Citi analyst Yigal Nochomovitz maintains with a buy rating, and adjusts the target price from $34 to $45.
Barclays analyst Peter Lawson maintains with a buy rating, and maintains the target price at $33.
TD Cowen analyst Phil Nadeau maintains with a buy rating.
Mizuho Securities analyst Salim Syed maintains with a buy rating.
H.C. Wainwright analyst Edward White maintains with a buy rating, and adjusts the target price from $49 to $51.
Furthermore, according to the comprehensive report, the opinions of $Syndax Pharmaceuticals (SNDX.US)$'s main analysts recently are as follows:
Following the FDA's approval of Revuforj, it's noted that prior concerns regarding the three-month extension were baseless. Additionally, the boxed warning for differentiation syndrome anticipated for Revuforj is likely to become standard across the broader menin-inhibitor class, representing no unique competitive disadvantage.
The company announced the FDA approval of REVUFORJ, revumenib, for relapsed or refractory acute leukemia with KMT2A translocation in adults and pediatric patients, which occurred 6-weeks before the expected PDUFA date. The safety and efficacy on the label align with expectations, and the recommendation for initial QTc monitoring during treatment is not seen as burdensome.
Here are the latest investment ratings and price targets for $Syndax Pharmaceuticals (SNDX.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
